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Xinhua Flora Hu 
SURVIVAL ANALYSIS FOR THE ASSOCIATION BETWEEN ANTI-
HYPERTENSIVE MEDICATION AND TIME TO DEMENTIA WITH COMPETING 
RISK 
Background: High blood pressure (HBP) is a common risk factor for dementia in 
elder population. Anti-hypertensive medications have been reported to associate with 
lower incidence rate of dementia in elder African Americans. The Apolipoprotein E 
(ApoE) ε4 allele has been shown to be associated with both increased dementia and 
hypertension risk. However, previous studies had not examined the association between 
anti-hypertensive medications by ApoE status accounting for the competing risk from 
death. 
Methods: This is a prospective observational cohort study in 1236 community-
dwelling hypertensive African Americans aged 65 years and older without dementia at 
baseline, with follow-up cognitive assessment and clinical evaluation for dementia 
diagnosis. Dementia-free mortality was considered as the competing risk.  Of these, 707 
participants were genotyped for ApoE status. Anti-hypertensive medication use was 
obtained from prescription records in the electronic medical records of the Indiana 
Network for Patient Care (INPC). Cox proportional cause-specific hazard (CSH) 
regression models were applied to assess the association between anti-hypertensive 
medication use and CSHs for dementia and death in ApoE ε4 carriers and non-carriers 
separately.  
Key results: In ApoE ε4 carriers, participants using anti-hypertensive 
medications had lower CSH of dementia compared to those not on anti-hypertensive 
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medications before adjusting for blood pressure (BP) (hazard ratio (HR), 0.365; 95% CI, 
0.170 – 0.785; p = 0.0099). The HR was no longer significant once BP control was 
adjusted (HR, 0.784; 95% CI, 0.197 – 3.123; p = 0.7303). Anti-hypertensive medications 
were not associated with dementia rate in non-carriers. In ApoE ε4 non-carriers, 
participants on anti-hypertensive treatment showed significantly lower CSH of death 
compared to those not on mediations adjusting for covariates and BP control (HR, 0.237; 
95% CI, 0.149 – 0.375; p < 0.0001). There was no significant association between anti-
hypertensive medication use and death in ApoE ε4 carriers. 
Conclusions: Anti-hypertensive medication was associated with lower dementia 
rate in ApoE ε4 carriers and that rate was primarily mediated through BP control. In non-
carriers, anti-hypertensive medication was significantly associated with lower mortality 
rate and this association appears to be independent of BP control. 
Sujuan Gao, Ph.D., Chair 
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Chapter One 
Introduction 
Dementia is a progressive degenerative brain condition with impairment in at 
least two neuropsychiatric or cognitive domains which are not explained by non-
degenerative or primary psychiatric disorders [1]. Dementia is not a single disease, but a 
syndrome; its symptoms, including memory loss, difficulty in planning and organizing, 
etc., are common to several brain disease. Risk factors for dementia includes age, family 
history, gender (female), smoking, high blood pressure (HBP), and diabetes [2]. 
A common risk factor for dementia is hypertension, which is one of the most 
prevalent chronic diseases in older adults in the United States [3-5].  The age-adjusted 
prevalence of hypertension was 29% in 2011-2012 in U.S. adults, among which 76% 
were taking medication to lower their blood pressure (BP), and 52% had their BP 
controlled to below 140/90 mm Hg [6]. A recent meta-analysis of prospective studies 
showed both systolic blood pressure (SBP) and diastolic blood pressure (DBP) were 
positively correlated with the risk of dementia in the population aged ≥ 65 years in a 
dose-response fashion [7].  
Hypertension prevalence is particularly high in African Americans [8]. The 
previous studies showed that anti-hypertensive medications were significantly associated 
with lower risk of incident dementia in older hypertensive African Americans through 
better BP control [9, 10].  
Apolipoprotein E ε4 (ApoE ε4) gene is a major genetic risk factor for late-onset 
AD [11, 12] and hypertension [13, 14]. Hypertension and ApoE ε4 genotypes showed a 
synergistic effect on the acceleration of cognitive decline [15-18] and AD [19]. ApoE ε4 
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carriers who had HBP but not using anti-hypertensive medications had been shown to 
have elevated risk of AD dementia [20]. In previous studies including both ApoE ε4 
carriers and non-carriers, the significant association between anti-hypertensive 
medication and dementia rate was no longer significant after adjusting for ApoE ε4 
genotypes suggesting a potential role for ApoE in the relationship between anti-
hypertensive medication and dementia rate [9, 10]. 
Death is an inevitable factor in cohort studies of elderly participants [21]. Since 
the study design uses periodic evaluation to determine dementia status, the occurrence of 
death precludes the determination of dementia status [22]. Loss to follow-up due to death 
would be non-ignorable when the exposure variable of interest, anti-hypertensive 
medication use in my research, may be associated with mortality. Including death into 
survival analysis as a competing risk reduces potential bias in the risk estimate of 
dementia [23, 24]. Cox proportional cause-specific hazard (CSH) regression model is 
appropriate for causal analysis in the presence of competing risks [25]. 
The current study performed survival analysis to estimate the association between 
anti-hypertensive medication and time-to-dementia, with death as a competing risk, in 
hypertensive ApoE ε4 carriers and non-carriers, respectively. In this competing risk 
setting, time to incident dementia and time to death without dementia are two competing 
survival outcomes, i.e. participants reach the endpoint for either of the two outcomes.  
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Chapter Two 
Methods 
The current study is a secondary data analysis using data collected as part of the 
Indianapolis-Ibadan Dementia Project [9].  
 
Study population 
The Indianapolis-Ibadan Dement Project was a prospective cohort study. This 
analysis uses the cohort from the African Americans in Indianapolis, U.S.A. In 1992, 
2212 of the community-dwellings no younger than 65 years of age were recruited and 
enrolled. All participants underwent regular follow-up cognitive assessment and clinical 
evaluations by psychiatrists and neuropsychologists. Details of the cohorts have been 
described in the previous studies [9, 10]. Total of 1236 elder participants were included in 
this study. The study used a two-stage design, including a screening evaluation every 2 – 
3 years followed by a more comprehensive home-based clinical evaluation of participants 
selected by stratified random sampling based on screening results. The diagnostic criteria 
for dementia is from both the Diagnostic and Statistical Manual of mental Disorders, 
Revised Third Edition (DSM-III-R) and the International Classification of Diseases, 10th 
Revision (ICD-10) [9, 10].  
 
 Study endpoints 
Baseline for each participant in this study was defined as the date of enrollment in 
the study. The primary study endpoint was the date of a dementia diagnosis for 
participants with incident dementia. The study endpoint of the competing risk was the 
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date of death for participants who had not been diagnosed dementia. The date of last IIDP 
evaluation was used for censoring.  
 
 Anti-hypertensive Medications 
The prescription for anti-hypertensive medication on each participant were 
recorded during the period of study from his/her enrollment. The details for collecting 
prescription data were described in previous studies [9, 10]. Anti-hypertensive 
medications were categorized into classes of drugs used, as shown in previous study [9]. 
In the current study, I did not include the category of anti-hypertensive medication in the 
statistical model. 
 
Blood pressure measures 
All consenting participants were measured for BP records, starting from the 
second follow-up evaluation in 1997 for those enrolled in the 1992 cohort; Seated SBP 
and DBP were measured three times from the left arm by trained interviewers with 
Omron digital input/output units (Omron Healthcare Inc., Bannockburn, IL) at 
approximately 15-min intervals [9]. The average of the three measures were recorded for 
statistical analysis. An indicator variable was derived to indicate suboptimally treated BP 
(> 140 mmHg systolic or > 90 mmHg diastolic). 
 
ApoE genotype 
ApoE genotypes were determined by gene amplification and cleavage with Hhal, 
with the DNA samples which had been extracted under standard procedures from fresh 
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blood spots collected on filter paper, from the consent participants who enrolled in 2001 
or before [9, 26].  
 
Statistical Analyses 
I compared participants’ characteristics by dividing participants into three 
mutually exclusive groups: those who developed dementia, those who died, and 
participants censored for both events.  One-way analysis of variance (ANOVA) and 
Fisher’s exact tests were used for continuous variables and categorical variables, 
respectively, to compare the characteristics of participants among the three groups.  
I next categorized the participants into two groups: one is consisted of participants were 
prescribed anti-hypertensive therapy and the other is consisted of participants who were 
not. Similarly, one-way ANOVA and Fisher’s exact tests were used for the comparison 
of the participant characteristics between the two groups. 
I plotted cumulative incidence function (CIF) curves of dementia and of death, 
and then performed Gray’s test to compare the CIFs over time between those received 
and those did not receive the anti-hypertensive medication. Gray’s tests were performed 
in ApoE ε4 carrier and non-carrier participants, respectively.  
I next plotted CIF curves of dementia and of death, performed Gray’s test to 
compare the CIFs over time among the participants with well controlled BP, 
suboptimally treated BP, and missing value of BP, respectively.  
Cox proportional cause-specific hazard (CSH) regression models were used to 
determine the association between anti-hypertensive medications and the hazard of 
dementia in ApoE ε4 carriers and non-carriers, respectively. Covariates include baseline 
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age, education, gender, and comorbid medical conditions. A second set of models 
included suboptimal BP control to determine whether association between medication use 
and dementia was mediated through BP control. 
p-values smaller than 0.05 were considered statistically significant. 
All statistical analyses were performed using the Statistical Analysis System 
(SAS) [Release Version 9.4, SAS Institute Inc, Cary, NC, US]. 
 
Ethics 
Informed consents were collected from all study participants. The study was 
approved by the Indiana University-Purdue University institutional review board (IRB). 
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Chapter Three 
Results 
 
Comparisons of Participant Characteristics 
Of the 1236 hypertensive participants who had not been diagnosed dementia at 
baseline, 114 (9%) developed dementia, 511 (41%) died without dementia, and 611 
(49%) were censored for both events. In Table 1, I compared the demographic 
characteristics, ApoE genotypes, BP measures, and comorbid conditions of the 
participants who ended with dementia, death, and censored, respectively. The participants 
who developed dementia were significantly older at baseline (76.9 ± 6.9 years old) and at 
endpoint (84.8 ± 6.8 years old), comparing to the other two groups. There were 
significant differences on the years of education among the three groups, where the group 
developed dementia showed the fewest years of education (8.8 ± 3.3). Males are more 
likely to die rather than to develop dementia or to be censored, compared to females. The 
participants who developed dementia are more likely to contain ApoE ε4 allele (46.3%), 
comparing to the other two groups (p-value = 0.1012). Those died without dementia 
showed the lowest ratio of receiving anti-hypertensive medication (60.7%) and of chronic 
renal disease comorbid (1.8%); those developed dementia showed the highest ratio of 
heart comorbid condition (49.1%). The participants being censored showed the highest 
ratio of cancer comorbid condition (47.8%). No significant differences had been detected 
among the groups with respect to the remaining variables in Table 1.  
In Table 2, I compared the demographic characteristics, the status of BP control, 
and the endpoints between the participants who received anti-hypertensive treatment and 
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who did not. Compared to those in the absence of anti-hypertensive treatment, the 
participants on anti-hypertensive medication showed bigger ratio of females (78.9% vs. 
65.7%), greater burden of heart comorbid condition (49.3% vs. 30.2%), chronic renal 
disease (8.0% vs. 4.0%), diabetes (41.9% vs. 26.9%), atrial fibrillation (12.2% vs. 5.7%), 
and cancer (50% vs. 27.1%). The participants receiving anti-hypertensive treatment 
showed higher ratio of developing dementia (10.0% vs. 7.6%) or being censored (52.0% 
vs. 44.5%), but less likely to die (38.0% vs. 47.9%). The participants on anti-hypertensive 
medication showed better controlled BP than those not on anti-hypertensive medication 
(63.4% vs. 48.2%). The mean age at endpoint in those on anti-hypertensive medication 
were older than those not on anti-hypertensive medication (82.2 ± 6.4 vs. 79.2 ± 6.7 
years).  
 
Comparison of CIFs of Dementia and of Death over Time between the Participants with 
and without Anti-hypertensive Medication, in ApoE ε4 Carriers and Non-carriers 
I used nonparametric model to compute the CIFs of dementia and of death over 
time. In ApoE ε4 carriers, the CIF curves of dementia over time apparently separated 
from about 5 years till the end of follow-up period between the participants with and 
without anti-hypertensive medication. Those received anti-hypertensive therapy showed 
smaller CIFs of dementia over time comparing to those did not receive (Fig.1A, p = 
0.1401). The CIFs of death over time did not separate between those on anti-hypertensive 
medication and those not on anti-hypertensive medication (Fig.1B, p = 0.4346). In ApoE 
ε4 non-carriers, the CIF curves of dementia over time did not show unambiguous change 
attributed to the anti-hypertensive treatment (Fig.1C, p = 0.2748). The CIF of death over 
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time in those received anti-hypertensive therapy significantly decreased comparing to 
those did not receive therapy at any time point during follow-up (Fig.1D, p < 0.0001).  
Briefly, anti-hypertensive therapy apparently decreased the risk of dementia, not of death, 
in ApoE ε4 carriers. In ApoE ε4 non-carriers, anti-hypertensive therapy significantly 
decreased the risk of death, not of dementia. These results suggested the associations 
between anti-hypertensive medication and time-to-dementia or time-to-death could be 
very different between in ApoE ε4 carriers and in non-carriers. 
 
Comparison of CIFs of Dementia and Death over Time among Participants with 
Different BP Control Status 
I computed and compared the CIFs of dementia and of death among the 
participants with distinct BP control levels (Fig. 2). The CIF of dementia over time in 
those with good BP control were apparently lower than of those with suboptimally 
treated BP (Fig.2A, p = 0.0962). The CIF of death over time in the participants with good 
BP control significantly decreased compared to those with suboptimally treated BP 
(Fig.2B, p < 0.0001). The above results suggested the association between BP control and 
the risk of dementia or of death.  
Interestingly, the participants with missing value of BP showed the highest values 
of CIFs of dementia and of death, comparing to the other two groups (Fig.2A – 2B). This 
result indicated the observations of BP were missing not at random (MNAR). How to 
model the missing data mechanism is a problem related to my study; however, it is 
beyond the scope of this Master thesis and I will leave it for future research.  
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The Association between Anti-hypertensive Medication and the CSH of Dementia and of 
Death in ApoE ε4 Carriers 
In Table 3, I present results from Cox proportional CSH regression models, which 
were applied on ApoE ε4 carriers and non-carriers, respectively. My primary interest is 
the association between anti-hypertensive medication and the CSH of dementia. I also 
assessed the association between anti-hypertensive medication and the CSH of death, 
which acted as the competing risk for dementia. BP control status, demographic 
characteristics, and comorbid medical conditions were covariates in my statistical 
models. 
ApoE ε4 carriers prescribed with any anti-hypertensive medication were found to 
have a significantly decrease of CSH of dementia (Table 3, HR, 0.365; 95% CI, 0.170 – 
0.785; p = 0.0099) compared to the carriers not on anti-hypertensive medication, 
adjusting for all covariates except BP control. After adjusting for BP control, the 
significance of the HR of dementia disappeared (Table 3, HR, 0.784; 95% CI, 0.197 – 
3.123; p = 0.7303). Suboptimally treated BP is likely to be a risk factor for the CSH of 
dementia, since the p-value was at the edge significance (Table 3, HR, 2.485; 95% CI, 
0.983 – 6.283; p = 0.0545). The above results demonstrated that anti-hypertensive 
medication was associated with the CSH of dementia in hypertensive elders, reducing the 
rate of the incidence of dementia by better control the BP level in ApoE ε4 carriers (Fig. 
3A).  
I also checked the association between anti-hypertensive medication and the CSH 
of death. The results were shown in Table 4. ApoE ε4 carriers with anti-hypertensive 
medication did not show significant change of CSH of death, adjusting for all covariates 
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except BP control (Table 4, HR, 0.923; 95% CI, 0.579 – 1.472; p = 0.7365). The HR was 
not significantly different after adjusting for BP control (Table 4, HR, 0.617; 95% CI, 
0.318 – 1.196; p = 0.1529). Suboptimally treated BP showed no association with the CSH 
of death (Table 4, HR, 1.519; 95% CI, 0.926 – 2.491; p = 0.0975). These HR estimates 
did not suggest the role of BP control in the occurrence of death in ApoE ε4 carriers. The 
rate (CSH) of death in ApoE ε4 carriers were not significantly associated with anti-
hypertensive medication (Fig. 3A).  
 
The Association between Anti-hypertensive Medication and the CSH of Dementia and of 
Death in ApoE ε4 Non-Carriers 
ApoE ε4 non-carriers who had received anti-hypertensive treatment were found to 
have no apparent change of CSH of dementia (Table 3, HR, 1.311; 95% CI, 0.558 – 
3.342; p = 0.9124) compared to the non-carriers not on anti-hypertensive medication, 
adjusting for all covariates except BP control. This HR did not change apparently after 
adjusting for BP control (Table 3, HR, 1.037; 95% CI, 0.265 – 4.060; p = 0.9588). The 
above results showed that anti-hypertensive medication was not associated with the 
incident rate (estimated by CSH) of dementia in ApoE ε4 non-carriers (Fig. 3B).  
ApoE ε4 non-carriers receiving anti-hypertensive treatment were found to have a 
significantly decrease of CSH of death compared to those did not receive anti-
hypertensive medication, adjusting for all covariates except BP control (Table 4, HR, 
0.448; 95% CI, 0.309 – 0.649; p < 0.0001). The HR of death retained after adjusting for 
BP control (Table 4, HR, 0.237; 95% CI, 0.149 – 0.375; p < 0.0001). Suboptimally 
treated BP was not shown to be a risk factor for death (Table 4, HR, 1.351; 95% CI, 
12 
0.889 – 2.053; p = 0.1586). I concluded from the above estimates that anti-hypertensive 
medication was significantly associated with the CSH of death without the involvement 
of BP control (Fig. 3B).  
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Chapter Four 
Discussion 
In 2017, nearly 50 million people suffered dementia worldwide. This number is 
expected to increase to 75 million by 2030, mainly attributed to population aging [27]. 
Without available disease-modifying treatments for dementia currently, the high 
prevalence of dementia will increase health care burden by increasing the costs of caring 
people for dementia [28]. Prevention and management of dementia have become the 
priority for public health in many countries [27]. For this purpose, I need to identify risk 
factors for dementia and to investigate the potential association between the medication 
interventions and the hazard of dementia. The current study assessed the association 
between anti-hypertensive medication use and the hazard of dementia in hypertensive 
elders separately for ApoE ε4 carriers and non-carriers. 
The association between anti-hypertensive medication and dementia rate differed 
by ApoE ε4 carrier status. For ApoE ε4 carriers, anti-hypertensive medication use was 
significantly associated with reduced dementia rate and the reduced rate appeared to be 
mediated via BP control. However, there was no significant association between anti-
hypertensive medication use and dementia rate in the non-carriers.  
The association between anti-hypertensive medication and death also differed by 
ApoE ε4 status. In non-carriers, those on medication had significantly reduced rate of 
death compared to those not on medication (HR, 0.448; 95% CI, 0.309 – 0.649; p < 
0.0001) and this rate remained after adjusting for BP control (HR, 0.237; 95% CI, 0.149 – 
0.375; p < 0.0001). In ApoE ε4 carriers, there was no significant association between 
medication and the rate of death. These results suggest that the associations between anti-
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hypertensive medication and the rate of dementia or of death are different between ApoE 
ε4 carriers and non-carriers.  
This differences in the estimated associations may indicate potential difference in 
the underlying mechanisms of the development of dementia and mortality risk between 
ApoE ε4 carriers and non-carriers. Further biomedical researches could help explore the 
related mechanisms.  
My currents results are consistent with previous findings of the association 
between anti-hypertensive medication use and dementia: the odds of incident dementia 
significantly reduced by 38% (odds ratio, 0.62; 95% CI, 0.45 – 0.84) and the rate of 
incident dementia significantly reduced by 43% (HR, 0.57; 95% CI 0.37–0.88) in the 
participants received anti-hypertensive medications, comparing to those did not receive 
[9, 10]. However, in these earlier studies, the researchers had not included death, the 
competing risk for dementia in the elders, into the statistical model to assess the risk of 
incident dementia [9]. This weakness was overcome in the present study with competing-
risk survival analytical model as the statistical method. I also assessed the association 
between anti-hypertensive medication and rate of death. Furthermore, I performed 
investigation in ApoE ε4 carriers and non-carriers separately. These analyses are the 
strength of my current study, providing detailed information for the investigation.  
In the current study, medication data were limited to the names of the medicine 
reported by participants. I don’t have the information on the dosage, frequency, and 
duration of the medication use. I am in the lack of longitudinal BP information. The 
baseline covariates were not balanced between the participants received anti-hypertensive 
treatment and those did not.  These are the major weakness of the present study. 
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Chapter Five 
Conclusion 
In conclusion, I found that the association between anti-hypertensive medication 
and dementia risk differed by ApoE ε4 carrier status after accounting for the competing 
risk due to death. In ApoE ε4 carriers, anti-hypertensive medication use was significantly 
associated with reduced dementia risk and the reduced risk appeared to be mediated via 
BP control. However, there was no significant association between anti-hypertensive 
medication use and dementia risk in non-carriers. In non-carriers, anti-hypertensive 
medication was significantly associated with lower mortality risk and this association 
appears to be independent of BP control. Further research is needed to confirm my 
findings in other populations.  
 
  
  
 
Table 1. Characteristics of Participants by Endpoint Status   
 
 
Characteristics 
 
Demented (alive or died) 
 
Died without dementia 
 
Loss of follow-up 
 
 
N 
 
Mean ± SD or no. (%) 
 
N 
 
Mean ± SD or no. (%) 
 
N 
 
Mean ± SD or no. (%) 
P value 
Baseline:        
Mean age (SD), years 114 76.9 ± 6.9 511 74.9 ± 6.6 611 74.4 ± 5.5 0.0004** 
Male, no. (%) 114 26 (22.8%) 511 161 (31.5%) 611 129 (21.1%)  0.0003** 
Years of education (SD) 114 8.8 ± 3.3 510 9.5 ± 2.9 610 10.5 ± 2.7 < 0.0001*** 
Stroke, no. (%) 114 7 (6.1%) 511 26 (5.1%) 611 37 (6.1%) 0.7565 
Heart comorbid condition, no. (%) 114 56 (49.1%) 511 232 (45.4%) 611 241 (39.4%)  0.0471 * 
Chronic renal disease, no. (%) 114 10 (8.8%) 511 9 (1.8%) 611 63 (10.3%)  < 0.0001*** 
Diabetes – type 1 or 2, no. (%) 114 41 (36.0%) 511 195 (38.2%) 611 219 (35.8%) 0.7250 
Atrial fibrillation, no. (%) 114 10 (8.8%) 511 63 (12.3%) 611 51 (8.4%) 0.0792 
Chronic obstructive pulmonary disease, no. (%) 114 5 (4.4%) 511 39 (7.6%) 611 52 (8.5%) 0.3422 
Cancer, no. (%) 114 41 (36.0%) 511 189 (37.0%) 611 292 (47.8%)  0.0005** 
ApoE ε4 carriers, no. (%) 82 38 (46.3%) 217 78 (36.0%) 408 138 (33.8%) 0.1012 
Baseline systolic blood pressure (SD), mmHg # 74 152.5 ± 26.0 312 145.6 ± 23.0 454 146.0 ± 21.8 0.0540 
Baseline diastolic blood pressure (SD), mmHg # 74 78.1 ± 14.9 312 77.3 ± 12.3 454 78.1 ± 12.2 0.6752 
Treatment (prescribed antihypertensive), no. (%) 114 82 (71.9%) 511 310 (60.7%) 611 424 (69.4%)  0.0035** 
Follow-up:        
Mean systolic blood pressure (SD), mmHg # 74 150.0 ± 21.5 312 144.8 ± 21.0 454 145.6 ± 19.2 0.1333 
Mean diastolic blood pressure (SD), mmHg # 74 76.6 ± 12.0 312 76.0 ± 10.9 454 76.2 ± 10.2 0.9018 
Blood pressure suboptimally treated, no. (%) ## 74 35 (47.3%) 312 130 (41.7%) 454 174 (38.3%) 0.2894 
Mean age at endpoint (SD), years 114 84.8 ± 6.8 511 79.2 ± 6.6 611 82.1 ± 6.1 < 0.0001*** 
# Average blood pressure measure per person from repeated blood pressure measurements 
## Defined as all blood pressure measurements > 140 mmHg systolic or > 90 mmHg diastolic pressure during follow-up 
*p < 0.05    **p < 0.01   ***p < 0.001   
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Table 2. Characteristics of Participants by Anti-hypertensive Treatment Status 
 
 
Characteristics 
 
Not prescribed antihypertensive 
 
Prescribed antihypertensive 
 
 
N 
 
Mean ± SD or no. (%) 
 
N 
 
Mean ± SD or no. (%) 
P value 
Baseline:      
Mean age (SD), years 420 75.3 ± 6.3 816 74.6 ± 6.0 0.0539 
Male, no. (%) 420 144 (34.3%) 816 172 (21.1%) < 0.0001*** 
Years of education (SD) 418 9.8 ± 3.1 816 10.0 ± 2.9 0.4308 
Stroke, no. (%) 420 19 (4.5%) 816 51 (6.2%) 0.2433 
Heart comorbid condition, no. (%) 420 127 (30.2%) 816 402 (49.3%) < 0.0001*** 
Chronic renal disease, no. (%) 420 17 (4.0%) 816 65 (8.0%) 0.0079** 
Diabetes – type 1 or 2, no. (%) 420 113 (26.9%) 816 342 (41.9%) < 0.0001*** 
Atrial fibrillation, no. (%) 420 24 (5.7%) 816 100 (12.2%) 0.0002** 
Chronic obstructive pulmonary disease, no. (%) 420 25 (6.0%) 816  71 (8.7%) 0.0930 
Cancer, no. (%) 420 114 (27.1%) 816 408 (50%) < 0.0001*** 
ApoE ε4 carriers, no. (%) 190 69 (36.3%) 517 185 (35.8%) 0.9296 
Follow-up:      
Demented (either died later or alive)  420 32 (7.6%) 816 82 (10.0%)  
0.0035** 
Died without dementia 420 201 (47.9%) 816 310 (38.0%) 
Loss of follow-up (alive without dementia) 420 187 (44.5%) 816 424 (52.0%) 
Blood pressure suboptimally treated, no. (%) # 162 84 (51.8%) 678 255 (37.6%) 0.0013** 
Mean age at endpoint (SD), years 420 79.2 ± 6.7 816 82.2 ± 6.4 < 0.0001*** 
# Defined as all blood pressure measurements > 140 mmHg systolic or > 90 mmHg diastolic pressure during follow-up 
*p < 0.05    **p < 0.01   ***p < 0.001 
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Table 3. Results of Cox PH Regression Model of Time-to-Dementia 
Variable ApoE ε4 Carriers (HR (95%CI), p) Non-carriers (HR (95%CI), p)  
Age at baseline 1.157 (1.092 – 1.225), <.0001 *** 1.121 (1.067 - 1.178), <.0001 *** 
M
odels w
ithout adjusting for BP control 
Years of education 0.917 (0.817 - 1.028), 0.1367 0.844 (0.762 – 0.934), 0.0011 ** 
Prescribed any anti-hypertensive medication (vs. Not prescribed anti-hypertensive medication) 0.365 (0.170 – 0.785), 0.0099 ** 1.311 (0.558 – 3.342), 0.9124 
Male (vs. Female) 0.417 (0.149 - 1.242), 0.1163 1.671 (0.776 – 3.596), 0.1892 
Heart comorbid condition 0.890 (0.414 - 1.910), 0.7643 0.988 (0.491 - 1.988), 0.9729 
Chronic renal disease 3.441 (1.135 - 10.434), 0.0290 * 0.810 (0.240 – 2.739), 0.7350 
Stroke 2.197 (0.588 – 8.199), 0.2417 1.696 (0.502 – 5.732), 0.3954 
Atrial fibrillation 0.553 (0.119 – 2.568), 0.4499 0.766 (0.315 – 1.865), 0.5573 
Chronic obstructive pulmonary disease 1.505 (0.480 – 4.722), 0.4834 N/A 
Cancer 0.980 (0.471 - 2.042), 0.9577 0.386 (0.198 – 0.752), 0.0052 ** 
Diabetes – type 1 or 2 0.505 (0.237 - 1.074), 0.0759 0.914 (0.429 - 1.948), 0.8167 
Age at baseline 1.211 (1.117 – 1.314), <.0001 *** 1.1434 (1.070 - 1.222), <.0001 *** 
M
odels w
ith adjusting for BP control 
Years of education 0.937 (0.798 - 1.101), 0.4284 0.787 (0.684 – 0.904), 0.0008 ** 
Prescribed any anti-hypertensive medication (vs. Not prescribed anti-hypertensive medication) 0.784 (0.197 – 3.123), 0.7303 1.037 (0.265 – 4.060), 0.9588 
Male (vs. Female) 0.854 (0.243 – 3.000), 0.8052 1.471 (0.525 – 4.122), 0.4624 
Heart comorbid condition 0.615 (0.218 - 1.734), 0.3578 2.201 (0.883 – 5.486), 0.0905 
Chronic renal disease 2.070 (0.513 – 8.351), 0.3068 1.272 (0.355 – 4.556), 0.7121 
Stroke 0.755 (0.092 – 6.211), 0.7937 1.975 (0.414 – 9.433), 0.3935 
Atrial fibrillation 0.558 (0.069 – 4.537), 0.5857 0.692 (0.241 – 1.986), 0.4940 
Chronic obstructive pulmonary disease 1.334 (0.344 – 5.174), 0.6771 N/A 
Cancer 1.018 (0.364 - 2.851), 0.9722 0.493 (0.220 – 1.106), 0.0861 
Diabetes – type 1 or 2 0.684 (0.257 - 1.819), 0.4469 0.338 (0.113 - 1.016), 0.0534 
Blood pressure suboptimally treated 2.485 (0.983 – 6.283), 0.0545  2.346 (1.015 – 5.418), 0.0460 * 
* p < 0.05          ** p < 0.01         *** p < 0.001  
  
 
19 
Table 4. Results of Cox PH Regression Model of Time-to-Death 
Variable ApoE ε4 Carriers (HR (95%CI), p) Non-carriers (HR (95%CI), p)  
Age at baseline 1.083 (1.045 – 1.123), <.0001 *** 1.100 (1.070 – 1.130), <.0001 *** 
M
odels w
ithout adjusting for BP control 
Years of education 0.984 (0.918 – 1.056), 0.6550 0.919 (0.869 – 0.972), 0.0032 ** 
Prescribed any anti-hypertensive medication (vs. Not prescribed anti-hypertensive medication) 0.923 (0.579 – 1.472), 0.7365 0.448 (0.309 – 0.649), <.0001 *** 
Male (vs. Female) 1.313 (0.803 – 2.148), 0.2781 2.123 (1.449 – 3.110), 0.0001 *** 
Heart comorbid condition 0.935 (0.602 – 1.450), 0.7627 1.249 (0.864 – 1.807), 0.2374 
Chronic renal disease 0.300 (0.072 – 1.248), 0.0978 0.215 (0.079 – 0.589), 0.0028 ** 
Stroke 0.762 (0.298 – 1.943), 0.5688 1.317 (0.657 – 2.640), 0.4379 
Atrial fibrillation 1.190 (0.555 – 2.553), 0.6548 0.770 (0.453 – 1.307), 0.3323 
Chronic obstructive pulmonary disease 0.960 (0.456 – 2.023), 0.9146 N/A 
Cancer 0.729 (0.469 – 1.133), 0.1596 1.031 (0.739 – 1.439), 0.8574 
Diabetes – type 1 or 2 0.789 (0.507 – 1.230), 0.2960 1.668 (1.158 – 2.404), 0.0061 ** 
Age at baseline 1.102 (1.055 – 1.152), <.0001 *** 1.077 (1.043 – 1.112), <.0001 *** 
M
odels w
ith adjusting for BP control 
Years of education 1.061 (0.972 – 1.158), 0.1846 0.926 (0.862 – 0.993), 0.0317 *  
Prescribed any anti-hypertensive medication (vs. Not prescribed anti-hypertensive medication) 0.617 (0.318 – 1.196), 0.1529 0.237 (0.149 – 0.375), <.0001 *** 
Male (vs. Female) 1.294 (0.704 – 2.378), 0.4062 1.851 (1.184 – 2.893), 0.0069 ** 
Heart comorbid condition 0.887 (0.511 – 1.539), 0.6696 1.656 (1.063 – 2.579), 0.0256 
Chronic renal disease 0.321 (0.076 – 1.353), 0.1215 0.222 (0.070 – 0.711), 0.0112 * 
Stroke 0.339 (0.080 – 1.425), 0.1397 0.812 (0.318 – 2.077), 0.6639 
Atrial fibrillation 1.489 (0.663 – 3.346), 0.3347 0.796 (0.449 – 1.410), 0.4344 
Chronic obstructive pulmonary disease 0.940 (0.403 – 2.190), 0.8856 N/A 
Cancer 0.737 (0.439 – 1.238), 0.2489 1.161 (0.792 – 1.702), 0.4457 
Diabetes – type 1 or 2 0.939 (0.558 – 1.578), 0.8119 1.440 (0.931 – 2.229), 0.1016 
Blood pressure suboptimally treated 1.519 (0.926 – 2.491), 0.0975 1.351 (0.889 – 2.053), 0.1586 
* p < 0.05          ** p < 0.01         *** p < 0.001  
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Figure 1. Cumulative Incidence Functions of Dementia and of Death over Time for ApoE ε4 Carriers and Non-carriers, by Anti-
hypertensive Medication Status 
  
 
21 
 
Figure 2. Cumulative Incidence Functions of Dementia and of Death over Time for Participants by BP Status  
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Figure 3. Scheme of the Association between Anti-hypertensive Medication and the Occurrence of Dementia and of Death in ApoE 
ε4 Carriers and Non-carriers 
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